Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.66)
# 4,092
Out of 5,162 analysts
57
Total ratings
30.61%
Success rate
-29.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $2.00 | +100.00% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $0.23 | +336.30% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $5.78 | +90.31% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $18.45 | +68.02% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.33 | +1,328.57% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $15.32 | +37.08% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.19 | -3.66% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.62 | +887.65% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.32 | +37,623.99% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $30.50 | -18.03% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $60.06 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $0.83 | +240,573.89% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.56 | +348.72% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.17 | +62.07% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $12.04 | +398.34% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.05 | +471.43% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.60 | +177.78% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.94 | +12,271.13% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $2.26 | +7,953.10% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.95 | +67,696.61% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $13.03 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.26 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.03 | +132.56% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $8.06 | +130,172.95% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.52 | +1,368.25% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $73.25 | +309.56% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $745.77 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $92.54 | -3.83% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $129.78 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.66 | +20,140.96% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.46 | +304.04% | 1 | Mar 19, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $2.00
Upside: +100.00%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $0.23
Upside: +336.30%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.78
Upside: +90.31%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $18.45
Upside: +68.02%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.33
Upside: +1,328.57%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $15.32
Upside: +37.08%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.19
Upside: -3.66%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.62
Upside: +887.65%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.32
Upside: +37,623.99%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $30.50
Upside: -18.03%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $60.06
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $0.83
Upside: +240,573.89%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.56
Upside: +348.72%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $6.17
Upside: +62.07%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $12.04
Upside: +398.34%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.05
Upside: +471.43%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.60
Upside: +177.78%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.94
Upside: +12,271.13%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $2.26
Upside: +7,953.10%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.95
Upside: +67,696.61%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $13.03
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $9.03
Upside: +132.56%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $8.06
Upside: +130,172.95%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.52
Upside: +1,368.25%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $73.25
Upside: +309.56%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $745.77
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $92.54
Upside: -3.83%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $129.78
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.66
Upside: +20,140.96%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.46
Upside: +304.04%